Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Return on Assets (2019 - 2025)

Historic Return on Assets for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to 0.75%.

  • BridgeBio Pharma's Return on Assets fell 1300.0% to 0.75% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.75%, marking a year-over-year decrease of 1300.0%. This contributed to the annual value of 0.74% for FY2024, which is 3800.0% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Return on Assets is 0.75%, which was down 1300.0% from 0.77% recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Return on Assets peaked at 0.51% during Q2 2021, and registered a low of 1.12% during Q4 2023.
  • Moreover, its 5-year median value for Return on Assets was 0.75% (2025), whereas its average is 0.77%.
  • As far as peak fluctuations go, BridgeBio Pharma's Return on Assets crashed by -3000bps in 2023, and later soared by 4900bps in 2024.
  • BridgeBio Pharma's Return on Assets (Quarter) stood at 0.69% in 2021, then fell by -25bps to 0.87% in 2022, then dropped by -29bps to 1.12% in 2023, then surged by 40bps to 0.66% in 2024, then dropped by -13bps to 0.75% in 2025.
  • Its Return on Assets stands at 0.75% for Q3 2025, versus 0.77% for Q2 2025 and 0.72% for Q1 2025.